Is NEKTAR THERAPEUTICS (NKTR) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.2% / 30% | 12.9% / 30% | 0.1% / 30% | 14.73% / 5% | ✗ NOT HALAL |
| DJIM | 5.2% / 33% | 12.9% / 33% | 0.1% / 33% | 14.73% / 5% | ✗ NOT HALAL |
| MSCI | 33.8% / 33% | 84.0% / 33% | 0.5% / 33% | 14.73% / 5% | ✗ NOT HALAL |
| S&P | 5.2% / 33% | 12.9% / 33% | 0.1% / 33% | 14.73% / 5% | ✗ NOT HALAL |
| FTSE | 33.8% / 33% | 84.0% / 33% | 0.5% / 50% | 14.73% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -87.5% | |
| Net Margin | -297.1% | |
| Return on Equity (ROE) | -217.9% | |
| Return on Assets (ROA) | -28.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$209M |
| Free Cash Flow | -$209M |
| Total Debt | $86M |
| Debt-to-Equity | 165.8 |
| Current Ratio | 5.0 |
| Total Assets | $280M |
Price & Trading
| Last Close | $70.97 |
| 50-Day MA | $59.38 |
| 200-Day MA | $46.21 |
| Avg Volume | 1.1M |
| Beta | 1.2 |
|
52-Week Range
$6.45
| |
About NEKTAR THERAPEUTICS (NKTR)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is NEKTAR THERAPEUTICS (NKTR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), NEKTAR THERAPEUTICS is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is NEKTAR THERAPEUTICS's debt ratio?
NEKTAR THERAPEUTICS's debt ratio is 5.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 33.8%.
What are NEKTAR THERAPEUTICS's key financial metrics?
NEKTAR THERAPEUTICS has a market capitalization of $2.0B, and revenue of $55M. The company maintains a gross margin of 100.0% and a net margin of -297.1%. Return on equity stands at -217.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.